Neurolixis - contact@neurolixis.com
copyright ©Neurolixis - 2011
Neurolixis Inc. is an early-stage biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of human central nervous system diseases including depression, schizophrenia, Parkinson's disease, ADHD and autism.
Neurolixis Inc. was founded in 2011 by highly experienced pharmaceutical industry professionals, with a world-class track record of CNS drug discovery, drug development, clinical trials, and company management.
Strategy
Neurolixis Inc. is focused on a dual strategy : licensing clinical assets and identifying and developing novel chemical entities that can target unmet needs in psychiatric and neurological disorders. More...
Research Grant
Neurolixis Inc. has been awarded a research grant by the Michael J. Fox Foundation to undertake a two year project targeting the symptoms of Parkinson's disease. The project will use pre-clinical models to investigate novel serotonergic "biased agonists". More...
News
Since being founded in 2011, Neurolixis has continuously built its projects and network of collaborations. Keep up-to-date with our progress by following the latest News